V ClinBio, a biopharmaceutical company focused on transforming existing compounds into differentiated new therapeutics, has acquired a 49.98% equity stake in Cellix Bio, a drug design and development company.  This transaction strengthens the companies’ existing collaboration focused on advancing best in class therapies across multiple drug categories promising to accelerate clinical success and fulfil unmet needs. Later this year V ClinBio expects to file an Investigation New Drug Appl...